



PRESS RELEASE

PIERREL DECIDES NOT TO SUBSCRIBE TO THE CONVERTIBLE LOAN NOTES OF THERAMETRICS HOLDING AG FOR A TOTAL OF CHF 3.3 MILLION (SOME € 3.0 MILLION)

Capua, 17 November 2015 – The Board of Directors of **Pierrel S.p.A.** (“**Pierrel**” or the “**Company**”) meeting today decided not to participate in the subscription of the second tranche, nor to possible further tranches of the convertible loan notes issued by THERAMetrics holding AG (“**THERAMetrics**”), parent company of the TCRDO Division of the Pierrel Group for a total of CHF 3.3 million (some € 3.0 million).

The Board of Directors in fact decided to continue to concentrate the financial resources of the Company on its core corporate business, represented by the industrial and commercial operations of the CMO and Pharma Divisions, controlled directly by the Company and by the Italian subsidiary Pierrel Pharma S.r.l. respectively. Pursuant to the agreements in force between THERAMetrics, on the one hand, and certain investors, on the other, the second tranche of the loan notes, as well as the further two tranches to be issued by THERAMetrics in the context of the transaction, will be fully subscribed by Fin Posillipo S.p.A. and Bootes S.r.l..

The decision of the Board of Directors of the Company not to participate in the subscription to the convertible loan of THERAMetrics was made considering the rules in force for transactions with related parties and, therefore, after having obtained the unanimous approval by the Related Party Committee of Pierrel, as Fin Posillipo S.p.A., counterparty to THERAMetrics within the scope of the convertible loan notes, is the leading shareholder in Pierrel with a holding in the related share capital of some 36.4% and Raffaele Petrone, Chairman of the Board of Directors of Pierrel, is also CEO and a relevant shareholder in Fin Posillipo S.p.A..

For further information in respect of the convertible loan notes issued by THERAMetrics holding AG refer to the press releases issued by the Company and by THERAMetrics on 16 and 21 October 2015, available at www.pierrelgroup.com and www.therametrics.com, as well as the information document published by the Company on 28 October 2015 pursuant to the applicable rules concerning transactions with related parties of major significance, at www.pierrelgroup.com, section *Investor Relations/Corporate Governance/Related Parties*.

* * *

Pierrel S.p.A. is a global supplier to the pharmaceutical, biopharmaceutical and life science industries, specialising in the discovery of medicinal product candidates and the repositioning of existing drugs for new therapeutic indications and clinical research (TCRDO Division), pharmaceutical production (Contract Manufacturing Division) and the development, registration and licensing of new drugs and medical devices (Pharma Division). Pierrel Group is listed on the MTA exchange which is organised and managed by Borsa Italiana and boasts over 60 years’ experience in the pharmaceutical sector, being one of Europe’s leading producers of local and dental anaesthetics. The TCRDO Division, working across Europe and the US, is recognised internationally for its research and development into tech based clinical research innovations with its Drug Repositioning and Repurposing System (“**DRR2.0**”) and Integrated Clinical Development Services (“**ICDS**”) for the pharmaceutical, biotechnology and biomedical industries. The parent company of the TCRDO Division (**THERAMetrics holding AG**, listed in the Swiss stock exchange) holds the innovative interactive **DRR2.0** platform, which runs on a database of 24



million scientific publications (being virtually all of those available in the field of biomedical literature), of over 4,900 drugs and of 9,400 illnesses. With this data, never before collected in one place and stored in the cloud, the Search and Match algorithm can show a researcher not only the candidate drug but also a detailed road map with indications of possible second medical uses. The database can be searched by molecule or by illness. Pierrel also has a production unit in Capua, close to Naples, Italy, that has been authorised by the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) for the aseptic production of injectable medicines. The subsidiary Pierrel Pharma S.r.l. has registered and distributes the Orabloc® dental anaesthetic in Canada, US, Russia and Europe. The registered office of Pierrel S.p.A. is in Capua (CE), Italy.

For further information:

Pierrel S.p.A.

Investor Relations

Raffaele Petrone

E-mail:

investor.relations@pierrelgroup.com

tel. +39 0823 626 111

fax +39 0823 626 228

Global Consult s.r.l.

Media Relations

Rossana Del Forno

E-mail: areacomunicazione@globalconsultsrl.com

tel. +39 333 6178665